Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002324-36
    Sponsor's Protocol Code Number:MK1026-003
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-05-20
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2020-002324-36
    A.3Full title of the trial
    A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
    Studio clinico di Fase 2 volto a valutare l’efficacia e la sicurezza di MK1026 in soggetti affetti da neoplasie maligne ematologiche
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
    Studio clinico di Fase 2 volto a valutare l’efficacia e la sicurezza di MK1026 in soggetti affetti da neoplasie maligne ematologiche
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberMK1026-003
    A.5.4Other Identifiers
    Name:INDNumber:133989
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMSD Italia Srl
    B.5.2Functional name of contact pointDivisione Ricerca Clinica
    B.5.3 Address:
    B.5.3.1Street AddressVia Vitorchiano, 151Via Vitorchiano, 151v
    B.5.3.2Town/ cityRoma
    B.5.3.3Post code00189
    B.5.3.4CountryItaly
    B.5.4Telephone number0039090636191371
    B.5.5Fax number00390636380371
    B.5.6E-mailgcto.italy@merck.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMK-1026
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2095393-15-8
    D.3.9.2Current sponsor codeMK-1026
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMK-1026
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2095393-15-8
    D.3.9.2Current sponsor codeMK-1026
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    B cell malignancies: Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenstroms macroglobulinemia
    Neoplasie delle cellule B: leucemia linfocitica cronica/linfoma linfocitico a piccole cellule; Trasformazione Richters; Linfoma a cellule mantellari; Linfoma della zona marginale; Linfoma follicolare; Macroglobulinemia di Waldenstroms
    E.1.1.1Medical condition in easily understood language
    B cell malignancies: Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenstroms macroglobulinemia
    Neoplasie delle cell B:leuc linfocitica cronica/linf linfoc a picc cell;Trasformazione Richters;Linfoma a cell mantellari;Linf della zona marginale;Linf follicolare; Macroglobulinemia di Waldenstroms
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10003899
    E.1.2Term B-cell lymphoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10008976
    E.1.2Term Chronic lymphocytic leukemia
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10026798
    E.1.2Term Mantle cell lymphomas
    E.1.2System Organ Class 100000004851
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10054693
    E.1.2Term Von Waldenstrom macroglobulinemia
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10076596
    E.1.2Term Marginal zone lymphoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    1. Part 1: To determine the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) of MK-1026.
    2. Part 2: Cohorts A to C (chronic Lymphocytic Leukemia [CLL]/Small Lymphocytic Lymphoma [SLL]): To evaluate the objective response rate (ORR) following administration with MK-1026 per International Workshop on CLL (iwCLL) criteria 2018 as assessed by independent central review (ICR).
    3. Part 2: Cohorts D to G (Richter’s Transformation [RT], Mantle cell Lymphoma [MCL], Marginal zone Lymphoma [MZL], Follicular Lymphoma [FL]): To evaluate the ORR following administration with MK-1026 per the Lugano criteria 2014 as assessed by ICR.
    4. Part 2: Cohort H (Waldenström’s Macroglobulinemia [WM]): To evaluate the ORR following administration with MK-1026 per International Workshop on WM (IWWM) 2014 as assessed by ICR.
    1. Parte 1: determinare la sicurezza e la tollerabilità e stabilire la dose raccomandata di Fase 2 (RP2D) di MK-1026.
    2. Parte 2: Coorti da A a C (Leucemia linfocitica cronica [CLL]/Linfoma linfocitico a piccole cellule [SLL]): valutare il tasso di risposta obiettiva (ORR) dopo la somministrazione di MK-1026 secondo i criteri dell'International Workshop on CLL (iwCLL) 2018 come valutati mediante revisione centrale indipendente (ICR).
    3. Parte 2: Coorti da D a G (Trasformazione di Richter [RT], Linfoma a cellule mantellari [MCL], Linfoma della zona marginale [MZL], Linfoma follicolare [FL]): valutare l'ORR in seguito la somministrazione di MK-1026 secondi i criteri di Lugano 2014 secondo la valutazione dell'ICR.
    4. Parte 2: Coorte H (Macroglobulinemia di Waldenström [WM]): valutare l'ORR in seguito alla somministrazione di MK-1026 secondo l'International Workshop on WM (IWWM), come valutato mediante ICR.
    E.2.2Secondary objectives of the trial
    1. Part 1: To characterize the pharmacokinetic (PK) profile of MK-1026.
    2. Part 1: To evaluate the ORR and duration of response (DOR) following administration with MK-1026 for CLL/SLL participants per iwCLL criteria 2018 as assessed by ICR.
    3. Part 2: All Cohorts: To determine the safety and tolerability of MK-1026.
    4. Part 2: All Cohorts: To characterize the PK profile of MK-1026.
    5. Part 2: Cohorts A to C (CLL/SLL): To evaluate DOR following administration with MK-1026 per iwCLL criteria 2018 as assessed by ICR.
    6. Pt 2: Cohorts D to G (RT, MCL, MZL, FL): To evaluate the DOR following administration with MK-1026 per the Lugano criteria 2014 as assessed by ICR.
    7. Part 2: Cohort H (WM): To evaluate the DOR of MK-1026 per IWWM 2014 as assessed by ICR
    1. Parte 1: caratterizzare il profilo farmacocinetico (PK) di MK-1026.
    2. Parte 1: valutare l'ORR e la durata della risposta (DOR) dopo la somministrazione di MK-1026 per i partecipanti CLL/SLL in base ai criteri iwCLL 2018 come valutato mediante ICR.
    3. Parte 2: Tutte le coorti: per determinare la sicurezza e la tollerabilità di MK-1026.
    4. Parte 2: Tutte le coorti: caratterizzare il profilo PK di MK-1026.
    5. Parte 2: Coorti da A a C (CLL/SLL): valutare la DOR dopo la somministrazione di MK-1026 in base ai criteri iwCLL 2018 come valutato mediante ICR.
    6. Pt 2: Coorti da D a G (RT, MCL, MZL, FL): valutare la DOR dopo la somministrazione di MK-1026 in base ai criteri di Lugano 2014 come valutato mediante ICR.
    7. Parte 2: Coorte H (WM): valutare la DOR di MK-1026 secondo la IWWM 2014 come valutato mediante ICR.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. In Part 1 and Part 2 (Cohorts A to C) has a confirmed diagnosis of CLL/SLL with;
    • A response to previous treatment of
    o At least 2 lines of prior therapy (Part 1 only)
    o Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible BTKi, BCL2i and PI3Ki.
    o Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naïve.
    o Part 2 Cohort C: CLL/SLL participants with 17p deletion who are relapsed or refractory following at least 1 line of prior therapy.
    • Active disease for CLL/SLL clearly documented to initiate therapy.
    • Provision of an evaluable core or excisional lymph node biopsy for biomarker analysis from an archival (<=60 days relative to the date of sample submission to the central laboratory) or newly obtained biopsy at Screening.
    2. Part 2 (Cohorts D to G):
    • Has a confirmed diagnosis of and response to previous treatment of one of the following:
    o Cohort D: participants with Richter’s transformation who are relapsed or refractory following at least 1 line of prior therapy.
    o Cohort E: participants with pathologically confirmed MCL, documented by either overexpression of cyclin D1 or t(11;14), who are relapsed or are
    refractory to chemoimmunotherapy and a covalent irreversible BTKi.
    o Cohort F: participants with MZL (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to chemoimmunotherapy and a covalent irreversible BTKi.
    o Cohort G: participants with FL who are relapsed or refractory to chemoimmunotherapy, immunomodulatory agents (i.e. lenalidomide +
    rituximab), and a PI3Ki.
    • Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan. A minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis.
    • Provide an evaluable core or excisional lymph node biopsy for biomarker analysis from an archival (<=60 days relative to the date of sample submission to the central laboratory) or newly obtained biopsy at Screening.
    3. Part 2 (Cohort H): confirmed diagnosis of WM; participants who are relapsed or refractory to chemoimmunotherapy and a covalent irreversible BTKi.
    • Active disease is defined as 1 of the following:
    o Systemic symptoms – Fever, drenching night sweats, fatigue, weight loss, and/or severe neuropathy.
    o Physical findings – Symptomatic or bulky (>=5 cm) lymphadenopathy, symptomatic hepatomegaly, and/or symptomatic splenomegaly.
    o Laboratory abnormalities – Hemoglobin <=10 g/dL or platelet count <100,000/microL.
    o Coexisting disease – Immunoglobulin light chain amyloidosis with organ dysfunction, symptomatic cryoglobulinemia, cold agglutinin anemia, immune hemolytic anemia and/or thrombocytopenia, or nephropathy due to WM.
    • Have measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM >=4500 g/dL; or bone marrow infiltration of 70%.
    • Provide an evaluable core or excisional lymph node biopsy for biomarker analysis from an archival (<=60 days relative to the date of sample submission to the central laboratory) or newly obtained biopsy at Screening.
    4. Have an ECOG performance status of 0 to 2 within 7 days prior to allocation.
    5. Have a life expectancy of at least 3 months, based on the investigator assessment.
    6. Have the ability to swallow and retain oral medication.

    For the remaining inclusion criteria refer to the protocol.
    1.Nella Parte1 e nella Parte2(Coorti da A a C)presenta una diagnosi confermata di CLL/SLL con;
    •Una risposta al precedente trattamento di
    oAlmeno 2 linee di terapia precedente(solo Parte 1)
    oParte2 CoorteA:partecipanti con CLL/SLL che sono recidivanti o refrattari alla terapia precedente con un covalente,BTKi,BCL2i e PI3Ki.
    oParte2 CoorteB:partecipanti con CLL/SLL che sono recidivanti o refrattari ad almeno 1 linea di terapia precedente e sono naïve al trattamento con BTKi.
    oParte2 CoorteC:partecipanti con CLL/SLL con delezione di 17p che sono recidivanti o refrattari ad almeno 1 linea di terapia precedente.
    •Malattia attiva per CLL/SLL chiaramente documentata per l'inizio della terapia
    •Fornitura di una biopsia del linfonodo core o escissionale valutabile per l'analisi dei biom da una biopsia archiviale(<= 60 giorni rispetto alla data di invio del campione al laboratorio centrale) o nuova ottenuta allo screening.
    2.Parte 2(Coorti da D a G):
    •Presenta una diagnosi confermata e una risposta al trattamento precedente di uno dei seguenti:
    oCoorteD:partecipanti con trasformazione di Richter recidivi o refrattari dopo almeno 1 linea di terapia precedente.
    oCoorteE:partecipanti con MCL confermata patologicamente, documentata da sovraespressione di ciclina D1 o t(11;14),recidivanti o refrattari alla chemioimmunoterapia e a un BTKi irreversibile covalente.
    oCoorteF:partecipanti con MLZ(incluso MZL splenico, nodale ed extra nodale)che sono recidivanti o refrattari alla chemioimmunoterapia e a un BTKi irreversibile covalente.
    oCoorteG:partecipanti con FL che sono recidivanti o refrattari alla chemioimmunoterapia, agli agenti immunomodulatori(ovvero lenalidomide + rituximab) e a un PI3Ki.
    •Avere una malattia misurabile definita come almeno 1 lesione che può essere misurata accuratamente in almeno 2 dimensioni con TC spirale. Una misurazione minima deve essere >15 mm nel diametro maggiore o >10 mm nell'asse corto.
    •Fornire una biopsia del linfonodo core o escissionale valutabile per l'analisi dei biomarcatori da una biopsia archiviale(<= 60 giorni rispetto alla data di invio del campione al laboratorio centrale) o nuova ottenuta allo screening. Se un campione di linfonodi è considerato clinicamente non sicuro da eseguire e può essere inviato altro tessuto appropriato.
    3.Parte2(Coorte H):diagnosi confermata di WM; partec che sono recidivanti o refrattari alla chemioimmunoterapia e a un BTKi irreversibile covalente.
    •La malattia attiva è definita come 1 dei seguenti:
    oSintomi sistemici-Febbre, sudorazioni notturne abbondanti, stanchezza, perdita di peso e/o grave neuropatia.
    oRisultati fisici-Linfoadenopatia sintomatica o voluminosa(>= 5cm),epatomegalia sintomatica e/o splenomegalia sintomatica.
    oAnomalie di laboratorio-Emoglobina <= 10 g/dL o conta piastrinica <100.000/microL.
    oMalattia coesistente-Amiloidosi a catena leggera delle immunoglobuline con disfunzione d'organo, crioglobulinemia sintomatica, anemia da agglutinina fredda, anemia emolitica immunitaria e/o trombocitopenia o nefropatia da WM.
    •Avere una malattia misurabile, che soddisfa una qualsiasi delle seguenti condizioni: almeno 1 lesione che può essere misurata accuratamente in almeno 2 dimensioni con TC spirale(la misurazione minima deve essere >15 mm nel diametro più lungo o >10 mm nell'asse corto);IgM >= 4500 g/dL; o infiltrazione del midollo osseo del 70%.
    •Fornire una biopsia del linfonodo core o escissionale valutabile per l'analisi dei biomarcatori da una biopsia archiviale (<= 60 gg rispetto alla data di invio del campione al laboratorio centrale) o nuova ottenuta allo screening.
    4.Avere un performance status secondo l'ECOG da 0 a 2 nei 7 giorni precedenti l'assegnazione.
    5.Avere un'aspettativa di vita di almeno 3 mesi, in base alla valutazione dello sperimentatore.
    6.Avere la capacità di ingoiare e trattenere i farmaci per via orale.

    Per i restanti criteri di inclusione fare riferimento al protocollo.
    E.4Principal exclusion criteria
    1. Part 1 and Part 2 participants: active HBV/HCV infection. See Inclusion Criteria 7 (HBV) and 8 (HCV) for requirements.
    2. Has a history of malignancy <=3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
    3. Has active CNS disease.
    4. Has an active infection requiring systemic therapy.
    5. Has a known history of HIV infection. No HIV testing is required unless mandated by local health authority.
    6. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
    7. Has QTc prolongation (defined as a QTcF >450 msecs) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min).
    8. Has received prior systemic anti-cancer therapy within 4 weeks prior to allocation.
    9. Is currently being treated with the following drugs:
    •CYP 2C9 substrates with a narrow therapeutic index (such as warfarin, phenytoin)
    •CYP 2C8 substrates with a narrow therapeutic index (such as paclitaxel)
    •CYP 2C19 substrates with a narrow therapeutic index (such as S-mephenytoin)
    •CYP 2D6 substrates with a narrow therapeutic index (such as thioridazine, pimozide)
    •P-gp substrates with a narrow therapeutic index (such as digoxin)
    10. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
    11. Prior exposure to non-covalent, reversible BTK inhibitors.
    12. Has a known psychiatric or substance abuse disorder that would interfere with the participant’s ability to cooperate with the requirements of the study.
    13. Has any clinically significant gastrointestinal abnormalities that might alter absorption.
    1.Partecipanti alla Parte 1 e alla Parte 2: infezione attiva da HBV/HCV. Vedere Criteri di inclusione 7 (HBV) e 8 (HCV) per i requisiti.
    2.Presenta un'anamnesi di malignità <= 3 anni prima della firma del consenso informato, fatta eccezione per il carcinoma a cellule basali o della cute a cellule squamose adeguatamente trattato o il tumore della cervice in situ.
    3.Presenta una malattia attiva del SNC.
    4.Presenta un'infezione attiva che richiede una terapia sistemica.
    5.Ha un'anamnesi nota di infezione da HIV. Non è richiesto alcun test per l'HIV se non reso obbligatorio dall'autorità sanitaria locale.
    6.Presenta un'anamnesi o evidenza attuale di qualsiasi condizione, terapia o anomalia di laboratorio che potrebbe confondere i risultati dello studio, interferire con la partecipazione del partecipante per tutta la durata dello studio o se partecipare non è nel miglior interesse del partecipante, secondo l'opinione dello sperimentatore responsabile del trattamento.
    7.Presenta prolungamento del QTc (definito come QTcF >450 msec) o altre anomalie significative dell'ECG, tra cui blocco AV tipo II di 2° grado, blocco AV di 3° grado o bradicardia (frequenza ventricolare inferiore a 50 battiti/min).
    8.Ha ricevuto una precedente terapia antitumorale sistemica nelle 4 settimane precedenti all'assegnazione.
    9.È attualmente in trattamento con i seguenti farmaci:
    •Substrati di CYP 2C9 con un indice terapeutico ristretto (come warfarin, fenitoina)
    •Substrati di CYP 2C8 con un indice terapeutico ristretto (come paclitaxel)
    •Substrati di CYP 2C19 con un indice terapeutico ristretto (come S-mefenitoina)
    •Substrati di CYP 2D6 con un indice terapeutico ristretto (come tioridazina, pimozide)
    •Substrati di P-gp con un indice terapeutico ristretto (come digossina)
    10.Sta attualmente partecipando o ha partecipato a uno studio condotto su un agente sperimentale o ha utilizzato un dispositivo sperimentale nelle 4 settimane precedenti la prima dose di trattamento dello studio.
    11.Precedente esposizione a inibitori reversibili non covalenti di BTK.
    12.Presenta un disturbo psichiatrico o di abuso di sostanze noto che interferirebbe con la capacità del partecipante di cooperare ai requisiti dello studio.
    13.Presenta anomalie gastrointestinali clinicamente significative che potrebbero alterare l'assorbimento.
    E.5 End points
    E.5.1Primary end point(s)
    1. Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
    2. Part 1: Number of participants experiencing adverse events (AEs)
    3. Part 1: Number of participants discontinuing study treatment due to AEs
    4. Part 2 (Cohorts A to C): Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
    5. Part 2 (Cohorts D to G): ORR per Lugano criteria 2014 as assessed by ICR
    6. Part 2 (Cohort H): ORR per International Workshop on Waldenström’s Macroglobulinemia (IWWM) 2014 as assessed by ICR
    1. Parte 1: numero di partecipanti che hanno riscontrato tossicità dose-limitante (DLT)
    2. Parte 1: numero di partecipanti che hanno manifestato eventi avversi (EA)
    3. Parte 1: numero di partecipanti che interrompono il trattamento in studio a causa di eventi avversi
    4. Parte 2 (Coorti da A a C): Tasso di risposta obiettiva (ORR) per International Workshop sui criteri 2018 della leucemia linfocitica cronica (iwCLL), valutato dalla revisione centrale indipendente (ICR)
    5. Parte 2 (Coorti da D a G): ORR secondo i criteri di Lugano 2014 come valutato dall'ICR
    6. Parte 2 (Coorte H): ORR per International Workshop sulla macroglobulinemia di Waldenström (IWWM) 2014 come valutato dall'ICR
    E.5.1.1Timepoint(s) of evaluation of this end point
    1. Up to ~56 days (Cycles 1-2, cycle = 28 days)
    2. Up to ~78 months
    3. Up to ~ 78 months
    4. Up to ~ 78 months
    5. Up to ~ 78 months
    6. Up to ~ 78 months
    1. Fino a ~ 56 giorni (cicli 1-2, ciclo = 28 giorni)
    2. Fino a ~ 78 mesi
    3. Fino a ~ 78 mesi
    4. Fino a ~ 78 mesi
    5. Fino a ~ 78 mesi
    6. Fino a ~ 78 mesi
    E.5.2Secondary end point(s)
    1. Part. 1: Area Under the Curve (AUC) of MK-1026
    2. Part. 1: Minimum Concentration (Cmin) of MK-1026
    3. Part 1: Maximum Concentration (Cmax) of MK-1026
    4. Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
    5. Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
    6. Part 2 (All Cohorts): Number of participants experiencing AEs
    7. Part 2 (All Cohorts): Number of participants discontinuing study treatment due to AEs
    8. Part. 2 (All Cohorts): AUC of MK-1026
    9. Part. 2 (All Cohorts): Cmin of MK-1026
    10. Part 2 (All Cohorts): Cmax of MK-1026
    11. Part 2 (Cohorts A to C): DOR per iwCLL criteria 2018 as assessed by ICR
    12. Part 2 (Cohorts D to G): DOR per Lugano criteria 2014 as assessed by ICR
    13. Part 2 (Cohort H): DOR per IWWM 2014 as assessed by ICR
    1. Part. 1: Area sotto la curva (AUC) di MK-1026
    2. Part. 1: Concentrazione minima (Cmin) di MK-1026
    3. Parte 1: Concentrazione massima (Cmax) di MK-1026
    4. Parte 1: ORR secondo i criteri iwCLL 2018 come valutato dall'ICR
    5. Parte 1: Durata della risposta (DOR) secondo i criteri iwCLL 2018 come valutato dall'ICR
    6. Parte 2 (tutte le coorti): numero di partecipanti che hanno avuto eventi avversi
    7. Parte 2 (tutte le coorti): numero di partecipanti che interrompono il trattamento in studio a causa di eventi avversi
    8. Part. 2 (Tutte le coorti): AUC di MK-1026
    9. Part. 2 (Tutte le coorti): Cmin di MK-1026
    10. Parte 2 (tutte le coorti): Cmax di MK-1026
    11. Parte 2 (Coorti da A a C): DOR secondo i criteri iwCLL 2018 come valutato dall'ICR
    12. Parte 2 (Coorti da D a G): DOR secondo i criteri di Lugano 2014 come valutato dall'ICR
    13. Parte 2 (Coorte H): DOR per IWWM 2014 come valutato da ICR
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. At designated time points (up to ~57 days)
    2. At designated time points (up to ~57 days)
    3. At designated time points (up to ~57 days)
    4. Up to ~78 months
    5. Up to ~78 months
    6. Up to ~78 months
    7. Up to ~78 months
    8. At designated time points (up to ~57 days)
    9. At designated time points (up to ~57 days)
    10. At designated time points (up to ~57 days)
    11. Up to ~78 months
    12. Up to ~78 months
    13. Up to ~78 months
    1. In momenti prestabiliti (fino a ~ 57 giorni)
    2. In momenti prestabiliti (fino a ~ 57 giorni)
    3. In momenti prestabiliti (fino a ~ 57 giorni)
    4. Fino a ~ 78 mesi
    5. Fino a ~ 78 mesi
    6. Fino a ~ 78 mesi
    7. Fino a ~ 78 mesi
    8. In momenti prestabiliti (fino a ~ 57 giorni)
    9. In momenti prestabiliti (fino a ~ 57 giorni)
    10. In momenti prestabiliti (fino a ~ 57 giorni)
    11. Fino a ~ 78 mesi
    12. Fino a ~ 78 mesi
    13. Fino a ~ 78 mesi
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    In aperto, gruppi paralleli
    Open, parallel group
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Colombia
    Israel
    Korea, Republic of
    Russian Federation
    Turkey
    Ukraine
    United States
    Denmark
    France
    Germany
    Greece
    Hungary
    Italy
    Netherlands
    Poland
    Portugal
    Romania
    Spain
    Sweden
    Switzerland
    United Kingdom
    Czechia
    Argentina
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS - The overall study ends when the last participant completes the last study-related telephone-call or visit, withdraws from the study, or is lost to follow-up (ie, the participant is unable to be contacted by the investigator).
    LVLS - Lo studio generale termina quando l'ultimo partecipante ha l'ultimo contatto telefonico o visita dello studio, si ritira dallo studio, o si perde al follow-up (cioè, il partecipante non può essere contattato dallo sperimentatore).
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 320
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 80
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 293
    F.4.2.2In the whole clinical trial 400
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-03-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-01-21
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:44:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA